SS Innovations International, Inc. (NASDAQ: SSII) announced a significant expansion in the utilization of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of September 8, 2026, a 79% increase from 7,885 at the end of 2025. The installed base of SSi Mantra systems grew 42% to 238 units, up from 168, reflecting accelerating adoption across global markets.
The company’s growth underscores the rising demand for cost-effective robotic surgery solutions, particularly in emerging economies. The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform. The system has been used for more than 170 types of surgical procedures, demonstrating its versatility and potential to address a wide range of medical needs.
Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments signal SS Innovations’ ability to penetrate new markets and expand the reach of advanced surgical care. Additionally, the company highlighted 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, showcasing the system’s efficiency and high-volume capacity.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. The company also believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones, if achieved, would open access to two of the largest and most lucrative healthcare markets, potentially driving further adoption and revenue growth.
The implications of this announcement are substantial for the global healthcare landscape. By offering a more affordable and accessible robotic surgery platform, SS Innovations aims to democratize advanced surgical care, particularly in regions where such technology has been prohibitively expensive. The company’s focus on cardiac surgery, pediatrics, and telesurgery demonstrates its commitment to addressing diverse surgical needs and improving patient outcomes.
For investors, the reported growth in procedures and installed base, coupled with upcoming regulatory decisions, positions SS Innovations as a company to watch in the competitive surgical robotics market. The full report is available at https://ibn.fm/DJILj, and the latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
